Dr Jean-Jacques Kiladjian at ASH 2014: Molecular profile of malignant clones in response to therapy in JAK2V617F-negative essential thrombocythaemia

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris, France) discusses using a next-generation sequencing approach to assess the mutational patterns of prognostically-relevant mutations (previously identified in myeloproliferative neoplasms) in calreticulin gene-mutated essential thrombocythaemia (ET) patients during interferon alpha (IFN-?) therapy.